1. Home
  2. CNNE vs RLMD Comparison

CNNE vs RLMD Comparison

Compare CNNE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNNE

Cannae Holdings Inc.

HOLD

Current Price

$14.68

Market Cap

609.0M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.50

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNNE
RLMD
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
609.0M
661.9M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
CNNE
RLMD
Price
$14.68
$6.50
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$20.25
$12.40
AVG Volume (30 Days)
445.9K
2.4M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
4.47%
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$499,700,000.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.37
154.83
52 Week Low
$10.46
$0.55
52 Week High
$21.96
$8.00

Technical Indicators

Market Signals
Indicator
CNNE
RLMD
Relative Strength Index (RSI) 57.87 47.38
Support Level $13.83 $6.17
Resistance Level $14.99 $7.28
Average True Range (ATR) 0.45 0.42
MACD 0.01 -0.00
Stochastic Oscillator 87.01 41.20

Price Performance

Historical Comparison
CNNE
RLMD

About CNNE Cannae Holdings Inc.

Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: